Scandinavian ChemoTech’s Chief Medical Officer, Suhail Mufti, provides an update on the clinical development and strategy of Medical Affairs
After the entry of TSE (Tumour Specific Electroporation™) in the curative lines of therapy for Head and Neck (H&N) cancer at AIIMS Jodhpur, ChemoTech brings updates on its long-term clinical targets and ongoing projects. Clinical strategy Apart from continued validation of the beneficial effects in superficial tumours and palliative care settings, the clinical development goals of TSE are focused on earlier and curative lines of cancer treatment in combination with other therapies, especially immunotherapy, including deep-seated tumours. Clinical Trial Progress 1.